NCT06751602View on ClinicalTrials.gov

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 30, 2028

Conditions
Rejection Chronic Renal
Interventions
DRUG

Belumosudil 200 mg QD

Belumosudil 200 mcg oral daily

DRUG

Placebo

Placebo (once daily)

Trial Locations (1)

77030

Houston Methodist Research Institute, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER